{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:40:47Z","timestamp":1784882447913,"version":"3.55.0"},"reference-count":49,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute on Aging","award":["AG 058738"],"award-info":[{"award-number":["AG 058738"]}]},{"name":"National Institute on Aging","award":["UL1TR000135"],"award-info":[{"award-number":["UL1TR000135"]}]},{"name":"National Institute on Aging","award":["P50 CA210964"],"award-info":[{"award-number":["P50 CA210964"]}]},{"name":"Mayo Clinic Center for Clinical and Translational Science","award":["AG 058738"],"award-info":[{"award-number":["AG 058738"]}]},{"name":"Mayo Clinic Center for Clinical and Translational Science","award":["UL1TR000135"],"award-info":[{"award-number":["UL1TR000135"]}]},{"name":"Mayo Clinic Center for Clinical and Translational Science","award":["P50 CA210964"],"award-info":[{"award-number":["P50 CA210964"]}]},{"name":"Mayo Clinic Hepatobiliary SPORE","award":["AG 058738"],"award-info":[{"award-number":["AG 058738"]}]},{"name":"Mayo Clinic Hepatobiliary SPORE","award":["UL1TR000135"],"award-info":[{"award-number":["UL1TR000135"]}]},{"name":"Mayo Clinic Hepatobiliary SPORE","award":["P50 CA210964"],"award-info":[{"award-number":["P50 CA210964"]}]},{"name":"Cholangiocarcinoma Foundation","award":["AG 058738"],"award-info":[{"award-number":["AG 058738"]}]},{"name":"Cholangiocarcinoma Foundation","award":["UL1TR000135"],"award-info":[{"award-number":["UL1TR000135"]}]},{"name":"Cholangiocarcinoma Foundation","award":["P50 CA210964"],"award-info":[{"award-number":["P50 CA210964"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Biliary tract cancers, including cholangiocarcinoma, gallbladder, and ampulla of Vater cancers, rank second among hepatobiliary cancers, known for their poor prognoses. The United States has witnessed a notable increase in intrahepatic cholangiocarcinoma incidence. This study examines the incidence and survival outcomes of biliary tract cancers in Olmsted County, Minnesota from 1976 to 2018. Using data from the Rochester Epidemiology Project (REP), residents aged 20 and above were analyzed across four eras. Incidence rates were calculated and adjusted for age and sex, and temporal trends were assessed using Poisson regression. Intrahepatic cholangiocarcinoma exhibited a significant escalation in incidence rates over time, while gallbladder cancers showed a decline among women. Median survival times for biliary tract cancers notably improved. These findings confirm the rising incidence of intrahepatic cholangiocarcinoma and suggest improving survival rates. Nevertheless, the overall prognosis for biliary tract cancers remains very poor, emphasizing the continual need for enhanced management strategies and further research.<\/jats:p>","DOI":"10.3390\/cancers16152720","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T08:02:27Z","timestamp":1722412947000},"page":"2720","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Incidence and Long-Term Outcomes of Biliary Tract Cancers in Olmsted County, Minnesota from 1976 to 2018"],"prefix":"10.3390","volume":"16","author":[{"suffix":"Jr.","given":"Eugene C.","family":"Nwankwo","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amerti","family":"Guta","sequence":"additional","affiliation":[{"name":"Center for Clinical and Translational Science, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1985-9160","authenticated-orcid":false,"given":"Scarlett S.","family":"Cao","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, TN 37232, USA"},{"name":"Department of Internal Medicine, Mayo Clinic School of Graduate Medical Education, Rochester, MN 55902, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Dong","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7022-1074","authenticated-orcid":false,"given":"Abubaker","family":"Abdalla","sequence":"additional","affiliation":[{"name":"Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA"},{"name":"Division of Hospital Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesam","family":"Taha","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, New York Presbyterian, Flushing, NY 11355, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-0465","authenticated-orcid":false,"given":"Joseph J.","family":"Larson","sequence":"additional","affiliation":[{"name":"Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yin","sequence":"additional","affiliation":[{"name":"Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3151-009X","authenticated-orcid":false,"given":"Gregory J.","family":"Gores","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Cleary","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA"},{"name":"Division of General Surgery, Department of Surgery, University of Toronto, Toronto, ON M5S 1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7885-8574","authenticated-orcid":false,"given":"Lewis R.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.soc.2019.06.012","article-title":"Biliary Tract and Primary Liver Tumors: Who, What, and Why?","volume":"28","author":"Hemming","year":"2019","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1056\/NEJM199910283411807","article-title":"Biliary tract cancers","volume":"341","author":"Gores","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Jiang, Y., Jiang, L., Li, F., Li, Q., Yuan, S., Huang, S., Fu, Y., Yan, X., Chen, J., and Li, H. (2022). The epidemiological trends of biliary tract cancers in the United States of America. BMC Gastroenterol., 22.","DOI":"10.1186\/s12876-022-02637-8"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: Epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.gastha.2021.10.010","article-title":"Increasing Incidence of Intrahepatic Cholangiocarcinoma Relative to Hepatocellular Carcinoma in the United States","volume":"1","author":"Lee","year":"2022","journal-title":"Gastro Hep Adv."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Koshiol, J., Yu, B., Kabadi, S.M., Baria, K., and Shroff, R.T. (2022). Epidemiologic patterns of biliary tract cancer in the United States: 2001\u20132015. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10286-z"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/oncolo\/oyac150","article-title":"Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017","volume":"27","author":"Javle","year":"2022","journal-title":"Oncologist"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5114\/ceh.2019.85166","article-title":"Epidemiology of gallbladder cancer","volume":"5","author":"Rawla","year":"2019","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/cncr.31942","article-title":"Biliary tract cancer incidence and trends in the United States by demographic group, 1999\u20132013","volume":"125","author":"Shiels","year":"2019","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1245\/s10434-006-9224-4","article-title":"Incidence pattern and survival for gallbladder cancer over three decades\u2014An analysis of 10301 patients","volume":"14","author":"Kiran","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/ijc.28161","article-title":"Biliary tract cancer incidence in the United States-Demographic and temporal variations by anatomic site","volume":"133","author":"Castro","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Qurashi, M., Vithayathil, M., and Khan, S.A. (2023). Epidemiology of cholangiocarcinoma. Eur. J. Surg. Oncol., 107064.","DOI":"10.1016\/j.ejso.2023.107064"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma","volume":"71","author":"Bertuccio","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2214\/AJR.20.23461","article-title":"Percutaneous Radiofrequency Ablation for Recurrent Intrahepatic Cholangiocarcinoma After Curative Resection: Multivariable Analysis of Factors Predicting Survival Outcomes","volume":"217","author":"Chu","year":"2021","journal-title":"Am. J. Roentgenol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2147\/OTT.S79316","article-title":"Transcatheter arterial chemoembolization with gemcitabine and oxaliplatin for the treatment of advanced biliary tract cancer","volume":"8","author":"Zhao","year":"2015","journal-title":"Onco Targets Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4251\/wjgo.v11.i6.489","article-title":"Clinical efficacy of gemcitabine and cisplatin-based transcatheter arterial chemoembolization combined with radiotherapy in hilar cholangiocarcinoma","volume":"11","author":"Zheng","year":"2019","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3322\/caac.21759","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jhep.2019.09.007","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis","volume":"72","author":"Clements","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"10646","DOI":"10.1038\/s41598-021-90175-w","article-title":"Primary sclerosing cholangitis and the risk of cancer, cardiovascular disease, and all-cause mortality: A systematic review and meta-analysis of cohort studies","volume":"11","author":"Aune","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ueg2.12204","article-title":"Risk of hepato-pancreato-biliary cancer is increased by primary sclerosing cholangitis in patients with inflammatory bowel disease: A population-based cohort study","volume":"10","author":"Yu","year":"2022","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/bs.acr.2022.02.001","article-title":"Inflammatory pathways and cholangiocarcinoma risk mechanisms and prevention","volume":"156","author":"Cadamuro","year":"2022","journal-title":"Adv. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Catanzaro, E., Gringeri, E., Burra, P., and Gambato, M. (2023). Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma: From Pathogenesis to Diagnostic and Surveillance Strategies. Cancers, 15.","DOI":"10.3390\/cancers15204947"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4251\/wjgo.v16.i1.13","article-title":"New trends in diagnosis and management of gallbladder carcinoma","volume":"16","author":"Pavlidis","year":"2024","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/jnci\/djz103","article-title":"Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies","volume":"111","author":"McGee","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/ajg.2012.173","article-title":"Biliary tract cancers in Olmsted County, Minnesota, 1976\u20132008","volume":"107","author":"Yang","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/ije\/dys195","article-title":"Data resource profile: The Rochester Epidemiology Project (REP) medical records-linkage system","volume":"41","author":"Grossardt","year":"2012","journal-title":"Int. J. Epidemiol."},{"key":"ref_31","unstructured":"Bureau USC (2024, July 07). 2022 7 July 2024. Olmsted County, Minnesota. Census Bureau, Available online: https:\/\/data.census.gov\/profile\/Olmsted_County,_Mi..?g=050XX00US27109."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1200\/EDBK_160831","article-title":"Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling","volume":"36","author":"Bridgewater","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1053\/jhep.2001.25087","article-title":"Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States","volume":"33","author":"Patel","year":"2001","journal-title":"Hepatology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.cgh.2007.05.020","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based case-control study","volume":"5","author":"Welzel","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/hep.510280404","article-title":"Risk of liver and other types of cancer in patients with cirrhosis: A nationwide cohort study in Denmark","volume":"28","author":"Sorensen","year":"1998","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.cgh.2019.07.060","article-title":"Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis","volume":"18","author":"Moon","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1053\/j.gastro.2004.12.048","article-title":"Risk factors of intrahepatic cholangiocarcinoma in the United States: A case-control study","volume":"128","author":"Shaib","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e201997","DOI":"10.1001\/jamanetworkopen.2020.1997","article-title":"Trends in the Burden of Chronic Liver Disease Among Hospitalized US Adults","volume":"3","author":"Hirode","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1158\/1055-9965.EPI-15-0199","article-title":"Gallbladder Cancer Incidence and Mortality, United States 1999\u20132011","volume":"24","author":"Henley","year":"2015","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3322\/canjclin.51.6.349","article-title":"Epidemiology and molecular pathology of gallbladder cancer","volume":"51","author":"Miquel","year":"2001","journal-title":"CA Cancer J. Clin."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/SLA.0b013e318176c4d3","article-title":"Intrahepatic cholangiocarcinoma: Rising frequency, improved survival, and determinants of outcome after resection","volume":"248","author":"Endo","year":"2008","journal-title":"Ann. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1038\/onc.2012.315","article-title":"Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","article-title":"Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma","volume":"45","author":"Graham","year":"2014","journal-title":"Hum. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1158\/1078-0432.CCR-21-4462","article-title":"FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation","volume":"28","author":"Casak","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","author":"Sahai","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000531458","article-title":"Recent Advances in Systemic Therapy for Advanced Intrahepatic Cholangiocarcinoma","volume":"13","author":"Yoo","year":"2023","journal-title":"Liver Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2147\/CMAR.S157156","article-title":"Biliary tract cancer: Current challenges and future prospects","volume":"11","author":"Ghidini","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/15\/2720\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:27:01Z","timestamp":1760110021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/15\/2720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":49,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["cancers16152720"],"URL":"https:\/\/doi.org\/10.3390\/cancers16152720","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]}}}